IL239740A0 - A method for cancer treatment based on k-ras mutational status - Google Patents
A method for cancer treatment based on k-ras mutational statusInfo
- Publication number
- IL239740A0 IL239740A0 IL239740A IL23974015A IL239740A0 IL 239740 A0 IL239740 A0 IL 239740A0 IL 239740 A IL239740 A IL 239740A IL 23974015 A IL23974015 A IL 23974015A IL 239740 A0 IL239740 A0 IL 239740A0
- Authority
- IL
- Israel
- Prior art keywords
- ras
- treating cancer
- cancer based
- mutation status
- mutation
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000035772 mutation Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361848793P | 2013-01-11 | 2013-01-11 | |
| US201361752417P | 2013-01-14 | 2013-01-14 | |
| US13/794,712 US20140199405A1 (en) | 2013-01-11 | 2013-03-11 | Method for treating cancer based on mutation status of k-ras |
| PCT/US2014/011097 WO2014110408A1 (en) | 2013-01-11 | 2014-01-10 | Method for treating cancer based on mutation status of k-ras |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL239740A0 true IL239740A0 (en) | 2015-08-31 |
Family
ID=51165319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL239740A IL239740A0 (en) | 2013-01-11 | 2015-07-01 | A method for cancer treatment based on k-ras mutational status |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140199405A1 (enExample) |
| EP (1) | EP2943184A4 (enExample) |
| JP (1) | JP2016506908A (enExample) |
| KR (1) | KR20150103746A (enExample) |
| AU (1) | AU2014205254A1 (enExample) |
| BR (1) | BR112015016466A2 (enExample) |
| CA (1) | CA2897581A1 (enExample) |
| HK (1) | HK1217292A1 (enExample) |
| IL (1) | IL239740A0 (enExample) |
| MX (1) | MX2015008889A (enExample) |
| WO (1) | WO2014110408A1 (enExample) |
| ZA (1) | ZA201504878B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| ES2678448T3 (es) | 2005-02-18 | 2018-08-10 | Abraxis Bioscience, Llc | Combinaciones y modos de administración de agentes terapéuticos y terapia combinada |
| TWI417114B (zh) | 2005-08-31 | 2013-12-01 | Abraxis Bioscience Llc | 具有增強穩定性之弱水溶性藥物之組合物及其製備方法 |
| ES2421354T3 (es) | 2006-08-11 | 2013-08-30 | Johns Hopkins University | Secuencias consenso codificantes de cánceres de mama y colorrectales humanos |
| CA2672618C (en) | 2006-12-14 | 2021-03-02 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| DK2155188T3 (da) * | 2007-06-01 | 2013-11-04 | Abraxis Bioscience Llc | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft |
| CN102460167B (zh) | 2009-04-15 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 不含朊病毒的纳米颗粒组合物和方法 |
| ES2580135T3 (es) | 2010-03-26 | 2016-08-19 | Abraxis Bioscience, Llc | Métodos de tratamiento de carcinoma hepatocelular |
| AU2011232862B2 (en) | 2010-03-29 | 2016-03-03 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| NZ628423A (en) | 2010-03-29 | 2016-03-31 | Abraxis Bioscience Llc | Methods of treating cancer |
| RU2576609C2 (ru) | 2010-06-04 | 2016-03-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечение рака поджелудочной железы |
| CA3063641A1 (en) | 2011-04-28 | 2012-11-01 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| DK2790675T3 (da) | 2011-12-14 | 2019-09-09 | Abraxis Bioscience Llc | Anvendelse af polymerexcipienser til frysetørring eller frysning af partikler |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| NZ630392A (en) | 2013-03-12 | 2016-10-28 | Abraxis Bioscience Llc | Methods of treating lung cancer |
| RU2015143490A (ru) | 2013-03-14 | 2017-04-26 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения рака мочевого пузыря |
| EP3369432A1 (en) | 2013-12-09 | 2018-09-05 | Targovax Asa | A peptide mixture |
| MX2016014414A (es) | 2014-05-06 | 2017-02-23 | Targovax Asa | Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico. |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| HUE070408T2 (hu) | 2015-06-29 | 2025-06-28 | Abraxis Bioscience Llc | Szirolimuszt és albumint tartalmazó nanorészecskék epitelioid sejtes tumorok kezelésében történõ alkalmazásra |
| BR112019006329A2 (pt) * | 2016-10-07 | 2019-06-25 | Abraxis Bioscience Llc | métodos de tratamento de câncer do trato biliar |
| EP3444272A1 (en) * | 2017-08-17 | 2019-02-20 | International-Drug-Development-Biotech | Treatment of ck8 positive cancers in relation with k-ras gene status |
| WO2019183146A1 (en) | 2018-03-20 | 2019-09-26 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| JP2022553426A (ja) | 2019-10-28 | 2022-12-22 | アブラクシス バイオサイエンス， エルエルシー | アルブミンおよびラパマイシンの医薬組成物 |
| WO2021226403A1 (en) * | 2020-05-08 | 2021-11-11 | Cardiff Oncology, Inc. | Methods of monitoring kras mutations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2678448T3 (es) * | 2005-02-18 | 2018-08-10 | Abraxis Bioscience, Llc | Combinaciones y modos de administración de agentes terapéuticos y terapia combinada |
| DK1913157T4 (en) * | 2005-06-28 | 2017-01-23 | Genentech Inc | EGFR and KRAS mutations for predicting patient response to EGFR inhibitor therapy. |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| HRP20140360T4 (hr) * | 2007-03-13 | 2022-06-10 | Amgen, Inc. | K-ras mutacije i terapija anti-egfr antitijelom |
| WO2011116181A1 (en) * | 2010-03-17 | 2011-09-22 | Caris Life Sciences, Inc. | Theranostic and diagnostic methods using sparc and hsp90 |
| NZ598588A (en) * | 2009-08-25 | 2014-05-30 | Abraxis Bioscience Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| NZ628423A (en) * | 2010-03-29 | 2016-03-31 | Abraxis Bioscience Llc | Methods of treating cancer |
| CA2795776A1 (en) * | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| WO2011146803A1 (en) * | 2010-05-20 | 2011-11-24 | Synta Pharmaceuticals Corp. | Method of treating lung adenocarcinoma with hsp90 inhibitory compounds |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| US9945862B2 (en) * | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| EP2823306A4 (en) * | 2012-03-09 | 2015-11-11 | Caris Life Sciences Switzerland Holdings Gmbh | BIOMARKER COMPOSITIONS AND METHODS |
| WO2013138371A1 (en) * | 2012-03-12 | 2013-09-19 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody |
-
2013
- 2013-03-11 US US13/794,712 patent/US20140199405A1/en not_active Abandoned
-
2014
- 2014-01-10 MX MX2015008889A patent/MX2015008889A/es unknown
- 2014-01-10 AU AU2014205254A patent/AU2014205254A1/en not_active Abandoned
- 2014-01-10 HK HK16105270.2A patent/HK1217292A1/zh unknown
- 2014-01-10 CA CA2897581A patent/CA2897581A1/en not_active Abandoned
- 2014-01-10 JP JP2015552819A patent/JP2016506908A/ja active Pending
- 2014-01-10 BR BR112015016466A patent/BR112015016466A2/pt not_active Application Discontinuation
- 2014-01-10 KR KR1020157021321A patent/KR20150103746A/ko not_active Withdrawn
- 2014-01-10 WO PCT/US2014/011097 patent/WO2014110408A1/en not_active Ceased
- 2014-01-10 EP EP14738060.4A patent/EP2943184A4/en not_active Withdrawn
-
2015
- 2015-07-01 IL IL239740A patent/IL239740A0/en unknown
- 2015-07-07 ZA ZA2015/04878A patent/ZA201504878B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015008889A (es) | 2015-11-13 |
| US20140199405A1 (en) | 2014-07-17 |
| JP2016506908A (ja) | 2016-03-07 |
| ZA201504878B (en) | 2016-10-26 |
| BR112015016466A2 (pt) | 2017-07-11 |
| WO2014110408A1 (en) | 2014-07-17 |
| AU2014205254A1 (en) | 2015-07-23 |
| CA2897581A1 (en) | 2014-07-17 |
| HK1217292A1 (zh) | 2017-01-06 |
| EP2943184A1 (en) | 2015-11-18 |
| KR20150103746A (ko) | 2015-09-11 |
| EP2943184A4 (en) | 2016-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201504878B (en) | Method for treating cancer based on mutation status of k-ras | |
| IL288181A (en) | Cancer treatment methods | |
| IL272905A (en) | Methods of treating pancreatic cancer | |
| IL304252A (en) | Cancer treatment methods | |
| IL289947A (en) | A method for treating cancer | |
| IL237791A0 (en) | A method for treating cancer | |
| IL245281A0 (en) | Methods and preparations for the treatment of cancer | |
| SG11201503893RA (en) | Method of treating cancer | |
| SG11201603050TA (en) | Methods for treating cancers | |
| IL240935B (en) | Methods of treating lung cancer | |
| EP3057594A4 (en) | Method of treating cancer | |
| EP2895206A4 (en) | METHOD FOR TREATING CARCINOMA | |
| SG11201508878WA (en) | Methods of treating cancer | |
| AP2015008803A0 (en) | Methods for treating psoriasis using an anti-il-23antibody | |
| IL240688A0 (en) | Pancreatic cancer treatment methods | |
| LT3016682T (lt) | Vėžio gydymo būdai | |
| EP3074040A4 (en) | Method of treating cancer | |
| ZA201507762B (en) | Methods of treating cancer | |
| PT2836176T (pt) | Técnica para tratar presbiopia | |
| AU2013904620A0 (en) | Method of treating cancer | |
| ZA201604162B (en) | Method for treating sulfide-free minerals |